Beckman Coulter, Oxford BioMedica, Sigma-Aldrich, GSK, Transinsight, Max Planck | GenomeWeb
Beckman Coulter Closes $235M Offering; Will Pay Off Debt Tied to Lumigen Buy
Beckman Coulter closed its tender offer for $235 million in senior notes, the company said this week.
The company said the money raised from the offering would go toward paying debts, a large chunk of which comes from its $185 million acquisition of Lumigen in October. Beckman said it would use the rest of the funds to fund research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.